» Articles » PMID: 17218256

Increased Myeloid Cell Responses to M-CSF and RANKL Cause Bone Loss and Inflammation in SH3BP2 "cherubism" Mice

Overview
Journal Cell
Publisher Cell Press
Specialty Cell Biology
Date 2007 Jan 16
PMID 17218256
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

While studies of the adaptor SH3BP2 have implicated a role in receptor-mediated signaling in mast cells and lymphocytes, they have failed to identify its function or explain why SH3BP2 missense mutations cause bone loss and inflammation in patients with cherubism. We demonstrate that Sh3bp2 "cherubism" mice exhibit trabecular bone loss, TNF-alpha-dependent systemic inflammation, and cortical bone erosion. The mutant phenotype is lymphocyte independent and can be transferred to mice carrying wild-type Sh3bp2 alleles through mutant fetal liver cells. Mutant myeloid cells show increased responses to M-CSF and RANKL stimulation, and, through mechanisms of increased ERK 1/2 and SYK phosphorylation/activation, they form macrophages that express high levels of TNF-alpha and osteoclasts that are unusually large. M-CSF and RANKL stimulation of myeloid cells that overexpress wild-type SH3BP2 results in similar large osteoclasts. This indicates that the mutant phenotype reflects gain of SH3BP2 function and suggests that SH3BP2 is a critical regulator of myeloid cell responses to M-CSF and RANKL stimulation.

Citing Articles

Chiral Supramolecular Hydrogels Regulating Both Osteoblastogenesis and Osteoclastogenesis.

Wu B, Dou X, Baddi S, Gao F, Zhao C, Feng C Gels. 2025; 11(2).

PMID: 39996655 PMC: 11855158. DOI: 10.3390/gels11020112.


Emerging Role of SH3BP2 as Regulator of Immune and Nonimmune Cells in Nephrotic Syndrome.

Srivastava T, Sharma M Glomerular Dis. 2025; 5(1):1-12.

PMID: 39991193 PMC: 11842026. DOI: 10.1159/000542703.


The bone phenotype associated with cherubism is independent of Caspase-1-dependent inflammasome activation in the mouse.

Rabhi B, Thomasseau S, Decrouy X, Cohen-Solal M, Deckert M, Coudert A PLoS One. 2025; 20(2):e0318826.

PMID: 39951467 PMC: 11828375. DOI: 10.1371/journal.pone.0318826.


Successful treatment of adult cherubism with a 60 mg denosumab 6-monthly regimen.

Le M, Sim F, Varatharajah K, Goh A, Yates C JBMR Plus. 2025; 9(2):ziae164.

PMID: 39830148 PMC: 11742083. DOI: 10.1093/jbmrpl/ziae164.


Autoinflammatory Bone Diseases.

Haslak F, Akay N, Gul U, Gunalp A, Kilic Konte E, Sahin S Balkan Med J. 2025; 42(1):5-13.

PMID: 39757386 PMC: 11725671. DOI: 10.4274/balkanmedj.galenos.2024.2024-11-129.